Immunic Therapeutics

Immunic Therapeutics

Germany - Grafelfing
Biotechnology

Focus: Small Molecules

Immunic Therapeutics is a life sciences company focused on Small Molecules.

NeurologyInfectious DiseasesOncologyImmunology
Funding Stage
PUBLIC
Open Jobs
5

Pipeline & Clinical Trials

Clinical Trials (1)
NCT05124795IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer
Phase 1
Phase 2
Clinical Trials (1)
NCT05054140Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
Phase 2
IMU-838
Covid 19
Phase 2
Clinical Trials (1)
NCT04516915IMU-838 and Oseltamivir in the Treatment of COVID-19
Phase 2
Clinical Trials (1)
NCT03846219MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
Phase 2
Phase 2
Clinical Trials (1)
NCT03341962Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
Phase 2
IMU-838
COVID-19
Phase 2/3
Clinical Trials (1)
NCT04379271A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
Phase 2/3
IMU-838 tablets
Multiple Sclerosis
Phase 3
Clinical Trials (1)
NCT05134441Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Phase 3
Clinical Trials (1)
NCT05201638Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Phase 3

Open Jobs (5)

Interview Prep Quick Facts
Portfolio: 8 clinical trials
Open Roles: 5 active jobs

Hiring Trend

Stable
5
Open Roles
+2
Added
-1
Filled/Removed

Based on last 4 crawl cycles